The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

ArriVent BioPharma, Inc. ( (AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...